All of Medytox starts from R&D.

Medytox R&D Vision and Accomplishments

Medytox concentrates our research capacity on botulinum toxin products as the main pipeline. Botulinum toxin related culture and separation/Refinement technology is a world-recognized, main competitive edge. Based on this, we are discovering various research technologies such as biofriendly filler development, toxin testing kit, anti-toxin drug development to to become a global biotech company.

R&D Vision

The Best at Botulinum Toxin Industry
The best technology
in botulinum toxin industry
After botulinum toxin researchers started the business in 2000, Korea’s first botulinum toxin medicine, Meditoxin (product name: Neuronox®, Siax®, etc.) was approved by KFDA and launched in the market in 2006. Furthermore, Medytoxin developed a next-generation botulinum toxin pharmaceutical distinguished in its safety, efficacy, and stability. When the next generation botulinum toxin enters the advanced markets such as the US and Europe, Medytox will go beyond Korea’s best botulinum toxin pharmaceutical corporation to become the world leader.
The Best at Medical Aesthetics
The best technology
in aesthetic plastic
surgery industry
After succeeding in developing botulinum toxin pharmaceuticals, Medytox developed a dermal filler, one of the major products in the aesthetic market. We succeeded in developing a filler using most biofriendly material hyaluronic acid and developed the manufacturing process and the analytical method and built GMP compliant facility for production. Medytox successfully secured the botulinum toxin and the filler in global medical aesthetic industry to become the best company in the global aesthetic industry.
Global Biotech Company
Global Biotech Company
Medytox has been working towards the vision of growing as a global biotech company. By utilizing infrastructure and biopharmaceutical development capacity built from botulinum toxin pharmaceutical development, we generate profit and reinvest it in developing innovative biopharmaceuticals. With the goal of success in developing new bio pharmaceuticals in the near future,we are cooperating with external R&D partners.

Medytox is continually growing as a global biotech company through continuous product development and investment.

R&D Accomplishments

Medytox shows biotechnology that changes the future through innovative technology and differentiated R&D.

01
First In-house development of 3 types of botulinum toxin, each with unique strengths in the world.
02
Development of various hyaluronic acid filler with distinct technology
03
Signed a License Agreement between Allergan Inc. (US) for new formulation of new botulinum toxin type A product

Ratio of R&D Investment to Sales

Sales
(Unit: million KRW)
200,000
150,000
100,000
50,000
10,000
0
17,189
2009
21,088
2010
21,074
2011
36,262
2012
39,141
2013
75,892
2014
88,505
2015
133,256
2016
181,239
2017
R&D Investment
(Unit: million KRW)
25,000
20,000
15,000
10,000
5,000
0
1,782
2009
5,213
2010
6,164
2011
6,394
2012
5,556
2013
7,605
2014
6,493
2015
18,638
2016
26,102
2017
Ratio of R&D Investment to Sales
2009 Ratio of R&D Investment to Sales

2009

10%
2010 Ratio of R&D Investment to Sales

2010

25%
2011 Ratio of R&D Investment to Sales

2011

28%
2012 Ratio of R&D Investment to Sales

2012

18%
2013 Ratio of R&D Investment to Sales

2013

14%
2014 Ratio of R&D Investment to Sales

2014

10%
2015 Ratio of R&D Investment to Sales

2015

7%
2016 Ratio of R&D Investment to Sales

2016

14%
2016 Ratio of R&D Investment to Sales

2017

14%